AI-Generated Antiviral is Intended to Treat Variants of Concern Such as Omicron and Delta Vancouver, BC – December 15, 2021 – Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced the company has generated and ordered compounds for validation in partnership with the University of British Columbia (UBC) and adMare BioInnovations to develop a novel SARS-CoV-2 Main Protease (3CLpro) inhibitor. The therapeutic is intended to be efficacious against the wild type and current variants of concern, including Delta and potentially Omicron, in the form of an antiviral pill. The COVID-19 drug discovery program is funded by Canada’s Digital Technology Supercluster, which is supported by the Canadian Ministry of Innovation, Science and Industry. “The Variational AI team is honored to partner with the University of British Columbia and adMare BioInnovations to work to address this most urgent medical need,” said Handol Kim, co-founder and CEO, Variational AI. “As society continues to grapple with COVID-19 variants, it is more important than ever to leverage the power of machine learning to accelerate our drug discovery efforts.” Variational AI has trained its generative AI algorithm…

Vancouver, BC – November 17, 2021 – Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecules, today announced that it has raised $US3.5 million ($CDN4.3 million) in seed funding. The investment round was led by Flying Fish Ventures, Alliance of Angels and A&E Investments, with participation from Lip-Bu Tan and Amarjit Gill, Silicon Valley entrepreneurs, investors and advisors.